Atossa Therapeutics Inc (ATOS) Stock Analysis
Verdict: WATCH (do not buy)
Clinical-stage cash exceeds market cap, offering a deep-value floor, but binary trial risks and zero revenue mandate a cautious stance.
Investment score: 42/100
Analysis as of
Is Atossa Therapeutics Inc stock worth reviewing? AI model thesis
ATOS is currently a 'broken' clinical-stage stock trading below its cash value. While analysts maintain a $10 target, the immediate lack of revenue and heavy burn rate (-$29.7M FCF) offset the attractive P/B of 0.65x. The model views this as a wait-and-see until Phase II data for (Z)-endoxifen provides a fundamental rerating.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Atossa Therapeutics Inc opportunities and risks
What speaks for ATOS
- Valuation Below Cash Value
What speaks against ATOS
- Cash Runway Exhaustion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ATOS | n/a | 0.0x | 0.2x | 0.0% | 0.0% | -144.9% |
| ATNM | n/a | 282.4x | 0.7x | 538.9% | -26078.9% | -90.4% |
| CVM | n/a | 0.0x | n/a | 0.0% | 0.0% | -178.3% |
| NXTC | n/a | 0.0x | n/a | 0.0% | 0.0% | -239.4% |
| LGVN | n/a | 12.2x | 0.0x | 65.1% | -1844.5% | -126.8% |
| NEUP | n/a | n/a | n/a | 104.7% | 272.0% | 282.8% |
| Peer median | n/a | 0.0x | n/a | 65.1% | 0.0% | -126.8% |
Frequently asked questions about Atossa Therapeutics Inc (ATOS)
Is ATOS stock a good investment?
The cached TradeMates AI model rates Atossa Therapeutics Inc as WATCH (do not buy) with an investment score of 42/100. ATOS is currently a 'broken' clinical-stage stock trading below its cash value. While analysts maintain a $10 target, the immediate lack of revenue and heavy burn rate (-$29.7M FCF) offset the attractive P/B of 0.65x. The model views this as a wait-and-see until Phase II data for (Z)-endoxifen provides a fundamental rerating. This is algorithmic model output, not personal investment advice.
Is ATOS stock a buy?
The TradeMates model verdict for ATOS is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.